Advertisement

Chemotherapy pp 309-314 | Cite as

Attempts to Overcome Methotrexate Resistance: The Value of Drug Resistant Cell Lines

  • Bridget T. Hill
  • L. A. Price
  • J. H. Goldie

Abstract

The potential antitumour effects of chemotherapy agents frequently are assessed in vitro and/or in vivo using experimental test systems consisting of tumour cells which show an inherent sensitivity to cytotoxic drugs (1–3). Since a major problem in cancer chemotherapy is that of drug resistance, there is a need to select agents effective against cells resistant to currently-available drugs. One approach, which has received little attention, is to use drug-resistant cells in culture.

Keywords

Folinic Acid Antitumour Activity Mixed Cell Population Drug Resistant Cell Line L5178Y Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Zubrod, C.G., Schepartz, S., Leiter, J., Endicott, K.M., Carresse, L.M. and Baker, C.G. Cancer Chemotherapy reports 50 (1966) 349.Google Scholar
  2. 2.
    Carter, S.K. Eur. J. Cancer 9 (1973) 833.PubMedGoogle Scholar
  3. 3.
    Dixon, G.J. Schabel, F.M., Skipper, H.E., Dulmadge, E. A. and Duncan, B. Cancer Res. (suppl) 21 (1961) 535.PubMedGoogle Scholar
  4. 4.
    Fischer, G.A. Biochem. Pharmacol. 11 (1960) 1233.CrossRefGoogle Scholar
  5. 5.
    Jackson, R.C. Personal communication.Google Scholar
  6. 6.
    Chu, M.Y. and Fischer, G.A. Biochem. Pharmacol. 17, (1968) 753.PubMedCrossRefGoogle Scholar
  7. 7.
    Hill, B.T., Goldie, J.H. and Price, L.A. Proc. Amm. Assoc. Cancer Res. 16 (1975) 44.Google Scholar
  8. 8.
    Barranco, S.C., Gerner, E.W., Burk, K.H. and Humphrey, R.M. Cancer Res. 33 (1973) 11.PubMedGoogle Scholar
  9. 9.
    Neol, G., Trouet, A., Zenebergh, A. and Tulkens, P. EORTC Int. Symp. Adriamycin Review (1975) 99. Brussels.Google Scholar
  10. 10.
    Burchenal, J.H. Goetchius, S.K., Stock, C.C. and Kltchings, G.H. Cancer Res. 12 (1952) 251.Google Scholar
  11. 11.
    Sugiura, K. Cancer Res. 13 (1953) 431.PubMedGoogle Scholar
  12. 12.
    Geils, G.F., Scott, C.W., Baugh, C.M., and Butterworth, C.E. Blood 38 (1971) 131.PubMedGoogle Scholar
  13. 13.
    Murphy, L.M., Ellison, R.R., Karnofsky, D.A. and Burchenal, J.H. J. Clin. Invest. 33 (1954) 1388.PubMedCrossRefGoogle Scholar
  14. 14.
    Goldie, J.H. Furness, M.E. and Price, L.A. Eur. J. Cancer 9 (1973) 709.PubMedGoogle Scholar
  15. 15.
    Hill, B.T., Price, L.A. and Goldie, J.H. Eur J. Cancer (1975) in press.Google Scholar
  16. 16.
    Goldman, I.D. In ‘Drug Resistance and Selectivity’. Ed. E. Mihich. (1973) 299. Academic Press.Google Scholar
  17. 17.
    Hill, B.T., Price, L.A., Harrison, S. and Goldie, J.H. Biochem Pharmacol. 24 (1975) 535.PubMedCrossRefGoogle Scholar
  18. 18.
    Hill, B.T., Goldie, J.H. and Price, L.A. Br. J. Cancer, 28 (1973) 263.PubMedCrossRefGoogle Scholar
  19. 19.
    Price, L.A., Goldie, J.H. and Hill, B.T. Br. Med. J. 2 (1975) 20.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1976

Authors and Affiliations

  • Bridget T. Hill
    • 1
  • L. A. Price
    • 2
  • J. H. Goldie
    • 3
  1. 1.Imperial Cancer Research FundLondonUK
  2. 2.Institute of Cancer ResearchLondonUK
  3. 3.St. Michael’s HospitalTorontoCanada

Personalised recommendations